Us Fda Grants Breakthrough Therapy Designation To Pfizers Gbs Vaccine Candidate To Help Prevent Infection In Infants Via Immunization Of Pregnant Women

Pfizer Inc. Announced That Its Investigational Group B Streptococcus (Gbs) Vaccine Candidate, Gbs6 Or Pf-06760805, Received Breakthrough Therapy Designation From The Us Food And Drug Administration (Fda) For The Prevention Of Invasive Gbs Disease Due To The Vaccine Serotypes In Newborns And Young Infants By Active Immunization Of Their Mothers During Pregnancy.The Fda Decision Is Informed By The Interim Analysis Of A Placebo-Controlled Phase 2 Study (Nct03765073), Evaluating The Safety And Immunogenicity Of Gbs6 In Healthy Pregnant Women Aged 18 To 40 Years, Who Were Vaccinated During The Second Or Early Third Trimester Of Pregnancy. The Study Remains Ongoing, And Pfizer Will Publish Outcomes From This Clinical Trial When It Is Completed.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!